X

Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C

by Dr. Trupti Shirole on  December 04, 2011 at 5:03 PM Clinical Trials News   - G J E 4
A -A +
Bristol-Myers Squibb Co. will collaborate with a unit of Johnson & Johnson to study a potential combination therapy for chronic hepatitis C.
 Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C
Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C

The companies will test the potentially positive effects of combining Johnson & Johnson's drug TMC435 with Bristol-Myers Squibb's daclatasvir. The clinical trials will begin in the first half of 2012 and will include a combination of the two drugs, the drugs plus pegylated interferon and ribavirin, and the drugs plus ribavirin.

The terms of their partnership were not disclosed.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

Most Popular News on Medindia

P
M
View All >>
X

Ask an Expert

Ask an Expert+
s
Alcoholic Liver Disease Epidemic Among Youth
 Alcoholic Liver Disease Epidemic Among Youth
S  Toddlers Served Cleaning Fluid at Toby Carvery
Toddlers Served Cleaning Fluid at Toby Carvery